Table 3.

FDA-approved drugs and clinical trials related to gasdermins

Clinical trial	FDA-approved drugs	Dose and schedule	Indication	Enrollment	Study Start/ Completion
NCT04594343 (phase 2)	Disulfiram	500 mg disulfiram orally or enterally daily for 14 days	Hospitalized subjects over the age of 50 with a diagnosis of moderate COVID-19	140	2020-11-20/2021-09-25
NCT04485130 (phase 2)	Disulfiram	Oral disulfiram for 5 consecutive days (cohort 1, 1000 mg/day; cohort 2, 2000mg/day)	COVID-19 patients with early mild to moderate symptoms	11	2021-08-18/2022-02-28
NCT04381936 (phase 2/3)	Including but not limited to dimethyl fumarate	Not mentioned	COVID-19 Inpatients	50,000 (estimated)	2020-03-19/ 2032-11 (estimated)

In NCT04381936, dimethyl fumarate has been shown to have no beneficial effect on COVID-19 inpatients and recruitment for this drug has been stopped